Skip to NavigationSkip to content

Amgen launches first biosimilar of best-selling Humira in Europe

Published on 16/10/18 at 10:24am

Amgen has announced the launch of a proprietary biosimilar version of Abbvie's best-selling drug Humira (adalimumab) across all European markets, beginning 16 October.

Amgevita, as the biosimilar is known, is the first such version of the world’s best-selling drug to secure approval from the European Commission, and as such is authorised for use in all the indications of its reference product, including moderate-to-severe rheumatoid arthritis; psoriatic arthritis; severe active ankylosing spondylitis (AS); moderate-to-severe chronic plaque psoriasis; moderate-to-severe Crohn's disease; moderate-to-severe ulcerative colitis, and more.

It is also approved for use in paediatric patients in a number of conditions, including moderate-to-severe Crohn's disease, severe chronic plaque psoriasis, enthesitis-related arthritis and polyarticular juvenile idiopathic arthritis.

Amgen secured approval for the therapy based on three Phase 3 trials which confirmed its biosimilarity to Humira with regards to safety and efficacy, showing no clinically meaningful differences between the two products.

"The launch of Amgevita in Europe is an important milestone for our biosimilars portfolio, expanding the range of treatment options for the millions of patients living with chronic inflammatory diseases," said Dr David M Reese, Executive Vice President of Research and Development at Amgen. "Amgevita is Amgen's second biosimilar to launch in Europe, demonstrating our commitment to providing patients with serious illnesses access to high-quality biological therapies."   

Scott Foraker, the company’s Vice President and General Manager of Biosimilars, added: "Building on our strong inflammatory disease presence in the United States, we are excited to develop our inflammation capabilities in Europe. As the first inflammation biosimilar from our portfolio to launch in Europe, Amgevita will extend our reach and help more patients gain access to this important class of therapies."

Matt Fellows

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches